echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet Neurol: Losartan is not yet effective in improving brain atrophy in patients with clinically diagnosed Alzheimer's disease

    Lancet Neurol: Losartan is not yet effective in improving brain atrophy in patients with clinically diagnosed Alzheimer's disease

    • Last Update: 2021-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com









    • 2014 Nian 7 May 22 to May 17, 2018, 261 participants entered the open-label phase



      Literature source: Kehoe PG, Turner N, Howden B, et al.
      Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
      Lancet Neurol.
      2021;20(11):895-906.
      doi:10.
      1016/S1474-4422(21)00263-5 Kehoe PG, Turner N, Howden B, et al.
      Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
      Lancet Neurol.
      2021;20(11):895-906.
      doi:10.
      1016/S1474-4422( 21)00263-5

      Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.